Literature DB >> 30853204

A Validated Scale for Assessing the Severity of Acute Infectious Mononucleosis.

Ben Z Katz1, Caroline Reuter2, Yair Lupovitch3, Kristen Gleason4, Damani McClellan4, Joseph Cotler4, Leonard A Jason4.   

Abstract

OBJECTIVES: To develop a scale for the severity of mononucleosis. STUDY
DESIGN: One to 5 percent of college students develop infectious mononucleosis annually, and about 10% meet criteria for chronic fatigue syndrome (CFS) 6 months following infectious mononucleosis. We developed a severity of mononucleosis scale based on a review of the literature. College students were enrolled, generally when they were healthy. When the students developed infectious mononucleosis, an assessment was made as to the severity of their infectious mononucleosis independently by 2 physicians using the severity of mononucleosis scale. This scale was correlated with corticosteroid use and hospitalization. Six months following infectious mononucleosis, an assessment is made for recovery from infectious mononucleosis or meeting 1 or more case definitions of CFS.
RESULTS: In total, 126 severity of mononucleosis scales were analyzed. The concordance between the 2 physician reviewers was 95%. All 3 hospitalized subjects had severity of mononucleosis scores ≥2. Subjects with severity of mononucleosis scores of ≥1 were 1.83 times as likely to be given corticosteroids. Students with severity of mononucleosis scores of 0 or 1 were less likely to meet more than 1 case definition of CFS 6 months following infectious mononucleosis.
CONCLUSIONS: The severity of mononucleosis scale has interobserver, concurrent and predictive validity for hospitalization, corticosteroid use, and meeting criteria for CFS 6 months following infectious mononucleosis.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic fatigue syndrome; hospitalization; infectious mononucleosis; severity of mononucleosis; steroids

Mesh:

Year:  2019        PMID: 30853204      PMCID: PMC6535355          DOI: 10.1016/j.jpeds.2019.01.035

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Acute infectious mononucleosis: characteristics of patients who report failure to recover.

Authors:  D S Buchwald; T D Rea; W J Katon; J E Russo; R L Ashley
Journal:  Am J Med       Date:  2000-11       Impact factor: 4.965

2.  Epstein-Barr virus-associated infectious mononucleosis and risk factor analysis for complications in hospitalized children.

Authors:  Ming-Han Tsai; Chih-Yi Hsu; Meng-Hsiu Yen; Dah-Chin Yan; Cheng-Hsun Chiu; Yhu-Chering Huang; Syh-Jae Lin; Tzou-Yien Lin
Journal:  J Microbiol Immunol Infect       Date:  2005-08       Impact factor: 4.399

3.  Predictors of the duration of infectious mononucleosis.

Authors:  J H Chretien; J G Esswein; W G Holland; C E McCauley
Journal:  South Med J       Date:  1977-04       Impact factor: 0.954

4.  Autonomic symptoms at baseline and following infectious mononucleosis in a prospective cohort of adolescents.

Authors:  Ben Z Katz; Julian M Stewart; Yukiko Shiraishi; Cynthia J Mears; Renee Taylor
Journal:  Arch Pediatr Adolesc Med       Date:  2011-08

5.  Chronic fatigue syndrome after infectious mononucleosis in adolescents.

Authors:  Ben Z Katz; Yukiko Shiraishi; Cynthia J Mears; Helen J Binns; Renee Taylor
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

6.  A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis.

Authors:  Henry H Balfour; Carol J Holman; Kristin M Hokanson; Meghan M Lelonek; Jill E Giesbrecht; Dana R White; David O Schmeling; Chiu-Ho Webb; Winston Cavert; David H Wang; Richard C Brundage
Journal:  J Infect Dis       Date:  2005-09-26       Impact factor: 5.226

7.  Infectious mononucleosis in university students in the United kingdom: evaluation of the clinical features and consequences of the disease.

Authors:  Karen F Macsween; Craig D Higgins; Karen A McAulay; Hilary Williams; Nadine Harrison; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

8.  Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study.

Authors:  Ian Hickie; Tracey Davenport; Denis Wakefield; Ute Vollmer-Conna; Barbara Cameron; Suzanne D Vernon; William C Reeves; Andrew Lloyd
Journal:  BMJ       Date:  2006-09-01

9.  Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load.

Authors:  Barbara Cameron; Mandvi Bharadwaj; Jacqueline Burrows; Chrysa Fazou; Denis Wakefield; Ian Hickie; Rosemary Ffrench; Rajiv Khanna; Andrew Lloyd
Journal:  J Infect Dis       Date:  2006-01-30       Impact factor: 5.226

10.  Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study.

Authors:  Pierre Tattevin; Yves Le Tulzo; Sophie Minjolle; Arnaud Person; Jean Marc Chapplain; Cedric Arvieux; Remi Thomas; Christian Michelet
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

View more
  4 in total

1.  Saliva Fatigue Biomarker Index As a Marker for Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in a Community Based Sample.

Authors:  Leonard A Jason; John Kalns; Alicia Richarte; Ben Z Katz; Chelsea Torres
Journal:  Fatigue       Date:  2021-10-27

Review 2.  Unexplained post-acute infection syndromes.

Authors:  Jan Choutka; Viraj Jansari; Mady Hornig; Akiko Iwasaki
Journal:  Nat Med       Date:  2022-05-18       Impact factor: 87.241

3.  Predictors for Developing Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following Infectious Mononucleosis.

Authors:  Leonard A Jason; Joseph Cotler; Mohammed F Islam; Jacob Furst; Ben Z Katz
Journal:  J Rehabil Ther       Date:  2022-02-21

4.  Risks for Developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in College Students Following Infectious Mononucleosis: A Prospective Cohort Study.

Authors:  Leonard A Jason; Joseph Cotler; Mohammed F Islam; Madison Sunnquist; Ben Z Katz
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.